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Abstract. Developing an effective malaria vaccine has been the goal of the scientific community for 
many  years.  A  malaria  vaccine,  added  to  existing  tools  and  strategies,  would  further  prevent 
infection and decrease the unacceptable malaria morbidity and mortality burden. Great progress 
has been made over the last decade and a number of vaccine candidates are in the clinical phases of 
development. The RTS,S malaria vaccine candidate, based on a recombinant 
is the most advanced of such candidates, currently undergoing a large phase III trial. RTS,S has 
consistently shown around 50% efficacy protecting against the first clinical episode of malaria, in 
some cases extending up to 4 years. 
malaria vaccine. This first vaccine against a human parasite is a groundbreaking achievement, but 
improved malaria vaccines conferring higher protection will be needed if the aspiration of ma
eradication is to be achieved.
Introduction. Malaria  is  considered  the  most 
important parasitic disease in the world. It is one of the 
ten leading causes of death in low income countries. 
During  2010,  it  was  estimated  that  malaria  caused 
around 216 million clinical episodes worldwide, being 
responsible for 655,000 deaths, the majority of which 
in African children.
1 In addition, it also contributes to 
impoverish local economies and consumes substantial 
health  resources.  Providing  a  comprehensive  set  of 
malaria control interventions to reduce incidence and 
mortality  is  projected  to  cost  around  3  US  billion 
dollars per year in Africa alone.
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Developing an effective malaria vaccine has been the goal of the scientific community for 
many  years.  A  malaria  vaccine,  added  to  existing  tools  and  strategies,  would  further  prevent 
decrease the unacceptable malaria morbidity and mortality burden. Great progress 
has been made over the last decade and a number of vaccine candidates are in the clinical phases of 
development. The RTS,S malaria vaccine candidate, based on a recombinant 
is the most advanced of such candidates, currently undergoing a large phase III trial. RTS,S has 
consistently shown around 50% efficacy protecting against the first clinical episode of malaria, in 
some cases extending up to 4 years. It is hoped that RTS,S will eventually become the first licensed 
malaria vaccine. This first vaccine against a human parasite is a groundbreaking achievement, but 
improved malaria vaccines conferring higher protection will be needed if the aspiration of ma
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in low income countries. 
During  2010,  it  was  estimated  that  malaria  caused 
around 216 million clinical episodes worldwide, being 
responsible for 655,000 deaths, the majority of which 
In addition, it also contributes to 
impoverish local economies and consumes substantial 
health  resources.  Providing  a  comprehensive  set  of 
malaria control interventions to reduce incidence and 
mortality  is  projected  to  cost  around  3  US  billion 
There  has  been  a  significant  increase  in  funding 
malaria control interventions and research over the last 
decade. In consequence, many countries have adopted 
evidence-based interventions to fight malaria, such as 
indoor residual spraying (IRS), long lasting insecticidal 
nets  (LLIN),  rapid  diagnostic  tests  (RDT)  and 
arteminisin-based  combination  therapies  (ACTs). 
Intermittent Preventive Treatment in Pregnant Woman 
and Infants (IPTp and IPTi respectively), which have 
demonstrated  to  be  effective  in  clinical  trials
innovative strategies using drugs for prevention which 
are currently recommended by WHO in areas of high 
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Developing an effective malaria vaccine has been the goal of the scientific community for 
many  years.  A  malaria  vaccine,  added  to  existing  tools  and  strategies,  would  further  prevent 
decrease the unacceptable malaria morbidity and mortality burden. Great progress 
has been made over the last decade and a number of vaccine candidates are in the clinical phases of 
development. The RTS,S malaria vaccine candidate, based on a recombinant P. falciparum protein, 
is the most advanced of such candidates, currently undergoing a large phase III trial. RTS,S has 
consistently shown around 50% efficacy protecting against the first clinical episode of malaria, in 
It is hoped that RTS,S will eventually become the first licensed 
malaria vaccine. This first vaccine against a human parasite is a groundbreaking achievement, but 
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d IPTi respectively), which have 
demonstrated  to  be  effective  in  clinical  trials,
3-4 are 
innovative strategies using drugs for prevention which 
are currently recommended by WHO in areas of high Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
transmission,  albeit  their  implementation  being 
variable and in some cases (IPTi) inexistent. Despite 
all the efforts made in the use and implementation of 
such malaria control interventions, it is thought that in 
order  to  decrease substantially  the  burden  of disease 
and  advance  towards  the  aspiration  of  malaria 
eradication,  effective  vaccines  against  malaria  are 
needed and should play a crucial role.
5
Despite  the  morbidity  and  mortality  burden 
attributable to malaria, there are other factors that make 
an effective malaria vaccine desirable. The resistance 
profile of malaria parasites to an increasing number of 
antimalarial  drugs  and  readily  available  insecticides, 
the  unequal  and  inadequate  distribution  of  malaria 
control  tools  in  different  settings  or  the  increased 
movement  of  migrant  populations  and  tourists  to 
endemic  areas  are  important  arguments  in  favour  of 
concentrating  resources  towards  malaria  vaccine 
research.  However, despite current  advances towards 
getting a effective malaria vaccine, scaling up available 
malaria control interventions seems the current realistic 
strategy to reduce the health burden of malaria,
6 and in 
many cases may probably be sufficient to approach the 
desired elimination goal.
7 The most advanced malaria 
vaccine, the RTS,S candidate, is currently undergoing a 
pre-licensure  trial,  and  although  it  constitutes  a 
historical advance in malaria research, more effective 
second generation vaccines will be required.
Brief History of Malaria Vaccines. The quest for an 
effective  malaria  vaccine  has  been  a  goal  for  the 
scientific  community  over  many  years.  Studies  with 
different species of malaria in rodents and birds have 
been  conducted  since  1910.
8 However,  the  most 
significant  advances  have  occurred  over  the  last  50 
years. Studies by Nussenzweig et al in the 60’s showed 
protective immunity in rodents after injecting irradiated 
rodent sporozoites.
9 Subsequent studies identified the 
circumsporozoite protein  (CSP),  a  surface  protein  of 
the sporozoite, as an important target for antibodies.
10
In  the  seventies,  Clyde  and  colleagues  showed  in 
humans that it was possible to obtain protection against 
infection  after  multiples  bites  of  irradiated 
sporozoites.
11 From  the  1980s  onwards,  major  focus 
was  given  to  identify  different  sporozoite  surface 
antigens,  potential  targets  of  monoclonal  and 
polyclonal antibodies. Some of them were part of early 
vaccine  candidates,  although  not  demonstrating 
significant protection. 
In  the  1980s,  researchers  from  South  America 
developed  an  asexual  blood  stage  peptide-based 
vaccine  (SPf66),  which  seemed  to  be  efficacious  in 
monkeys and humans.
12 However, subsequent studies 
conducted  in  different  malaria  endemic  countries, 
failed to provide similar results.
13-14 At about the same 
time,  GlaxoSmithKline  (GSK)  conducted  different 
studies  using  different  peptides  after  sequencing  the 
epitopes of protective antibodies directed to the central 
region of P. falciparum’s  CSP.
15 From all the different 
formulations, the construct that obtained better results 
in preclinical trials was one made with the hepatitis B 
virus  surface  antigen,  called  RTS,S.
16 This  construct 
was tested with different innovative adjuvants, AS04, 
AS03,  AS02  and  AS01,  the  latter  showing  the  best 
results
17 and currently undergoing a large phase III trial 
in different settings in Africa.
In parallel  to  the  development of  the  first  RTS,S 
vaccines,  different  studies  evaluated  the  response  to 
vaccines containing different peptides and proteins of 
the  asexual  blood  stage  of  the  parasite,  such  as  the 
apical membrane antigen 1 (AMA1), merozoite surface 
protein (MSP) 1, MSP2, MSP3, among others.
18 None 
of these vaccines have, however, shown as of today a 
satisfying  clinical  protection  similar  to  the  positive 
results shown by RTS,S. At the end of the 90’s new 
vaccines  aiming  to  enhance  cellular  immunity 
response, such as DNA vaccines and peptide vaccines, 
were developed, although they have not yet proven to 
be efficacious in humans
19. In recent years, new viral 
vectored  vaccines  have  been  developed  in  animal 
models obtaining promising results,
20-21 and now need 
to  be  assessed  in  malaria  endemic  countries,  where 
many vaccines have failed to demonstrate efficacy.
Desirable  Characteristics  for  a Malaria  Vaccine.
The  main  desirable  characteristics  for  a  malaria 
vaccine should include a good safety profile together 
with  a  high  efficacy  against  malaria  infection  and 
disease.  Nonetheless,  there  are  other  many  desirable 
conditions  that  need  to  be  addressed  together  with
malaria  vaccine  development.  Most  of  them  are 
depicted in table 1. Apart from the abovementioned
Table 1. Desirable characteristics of an ideal malaria vaccine
 Be effective preventing clinical disease, severe malaria 
and transmission in the community 
 Be completely safe for young infants and risk 
populations (pregnant women, people with immune 
deficiencies or other co-morbidities), with a similar 
safety profile as other EPI vaccines.
 Provide protection against the 5 species of malaria 
plasmodia.
 Provide long-lasting immunity
 Be administrable in the first months of life
 Single oral - dose regime compatible with vaccines of 
the expanded programme on immunization (EPI).
 Easily manufactured, deployed, stored and handled.
 Affordable for governments of low income countries.
 Stable at room temperature.
 Available for travelers of non endemic areas.Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure  1. Plasmodium  falciparum  Life  Cycle. 
vaccines), (2) Liver stages of parasite targetted by pre
sexual stage in the mosquito midgut and (5) midgut wall antigens (vector
parasite).
characteristics, the scientific community and decision 
makers have to ensure that effective and safe vaccines 
reach the target populations they have been intended 
to. As it has been suggested ensuring that “the limits of 
science are not constrained by the limits of systems" 
(excerpt by Dr Orin Levine, Johns Hopkins Bloomberg
School of Public Health)
22 must be an imperative when 
thinking of vaccines whose main beneficiaries live in 
low  income  countries  with  weak  deployment 
mechanisms.
How  Malaria  Vaccines  Work.  To  understand  the 
different approaches and targets used in preclinical and 
clinical  malaria  vaccine  research,  it  is  crucial  to 
understand the different stages of the parasite within 
the infection cycle.
The infection cycle. The parasite gets into human blood 
through the bite of a female mosquito Anopheles
in the blood of the infected person where it will only 
circulate  for  a  few  minutes,  the  parasite  rapidly 
migrates to the liver, infecting hepatic cells, where for 
a few days (incubation period) it multiplies and grows 
(liver stage). Then it is released into the blood stream, 
where they infect red blood cells (blood stage). In the 
blood  stage  they  multiply  and  differentiate  causing 
clinical symptomatology, before being picked up again 
in  a  mosquito  bite.  The  parasites  can  be  found  at 
: Open Journal System
Plasmodium  falciparum  Life  Cycle.  The  different  targets  of  malaria  vaccines.  (1)  Sporozoites  targetted  by  pre
vaccines), (2) Liver stages of parasite targetted by pre-erythrocytic  vaccines, (3) Asexual blood stages, mainly merozoites. (4) Parasite 
sexual stage in the mosquito midgut and (5) midgut wall antigens (vector-stage vaccines, indirectly acting against o
characteristics, the scientific community and decision 
makers have to ensure that effective and safe vaccines 
reach the target populations they have been intended 
ensuring that “the limits of 
by the limits of systems" 
Levine, Johns Hopkins Bloomberg
an imperative when 
thinking of vaccines whose main beneficiaries live in 
untries  with  weak  deployment 
To  understand  the 
different approaches and targets used in preclinical and 
clinical  malaria  vaccine  research,  it  is  crucial  to 
understand the different stages of the parasite within 
The parasite gets into human blood 
Anopheles. Once 
in the blood of the infected person where it will only 
circulate  for  a  few  minutes,  the  parasite  rapidly 
nfecting hepatic cells, where for 
a few days (incubation period) it multiplies and grows 
(liver stage). Then it is released into the blood stream, 
where they infect red blood cells (blood stage). In the 
blood  stage  they  multiply  and  differentiate  causing 
linical symptomatology, before being picked up again 
in  a  mosquito  bite.  The  parasites  can  be  found  at 
different stages inside the human body. The main ones 
are: sporozoites, when they are free in the blood after 
being  injected  by  the  mosquito,  schizonts  a
merozoites  within  the  liver  and  in  the  blood,  and 
gametocytes  in  the  blood,  which  are  sexually 
differentiated stages picked up by the mosquito during 
the blood meal and thus the only stages of the parasite 
responsible for transmission to the  mosquito an
next  human  being.  Inside  the  mosquito,  the  parasite 
also adopts different stages during a cycle of growth: 
gametes, right after they have been picked up in the 
blood  meal  and  deposited  in  the  mosquito  midgut 
lumen where they are fertilized; ookinetes
the evolution of the zygote produced by the fusion of 
gametocytes;  oocysts,  the  next  stage  that  continues 
developing in the epithelium of the midgut; and finally 
sporozoites, which are the product of a mature oocyst. 
They migrate to the salivary glands from the mosquito 
midgut, and these parasites are ready to infect the next 
human, perpetuating the life cycle (
Why is it so difficult to obtain a malaria vaccine?
absence of immune correlates of protection for malaria 
vaccines has been a longstanding obstacle in malaria 
vaccine  development.  The  discovery  of  a  biomarker 
which could behave as a reliable proxy of protection 
against clinical disease, together with t
a  predictive  animal  model  (currently  existing,  but 
The  different  targets  of  malaria  vaccines.  (1)  Sporozoites  targetted  by  pre-erythocityc
erythrocytic  vaccines, (3) Asexual blood stages, mainly merozoites. (4) Parasite 
stage vaccines, indirectly acting against ookinete stage of the 
different stages inside the human body. The main ones 
are: sporozoites, when they are free in the blood after 
being  injected  by  the  mosquito,  schizonts  and 
merozoites  within  the  liver  and  in  the  blood,  and 
gametocytes  in  the  blood,  which  are  sexually 
differentiated stages picked up by the mosquito during 
the blood meal and thus the only stages of the parasite 
responsible for transmission to the  mosquito and the 
next  human  being.  Inside  the  mosquito,  the  parasite 
also adopts different stages during a cycle of growth: 
gametes, right after they have been picked up in the 
blood  meal  and  deposited  in  the  mosquito  midgut 
lumen where they are fertilized; ookinetes, which are 
the evolution of the zygote produced by the fusion of 
gametocytes;  oocysts,  the  next  stage  that  continues 
developing in the epithelium of the midgut; and finally 
sporozoites, which are the product of a mature oocyst. 
y glands from the mosquito 
midgut, and these parasites are ready to infect the next 
human, perpetuating the life cycle (figure 1).
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Why is it so difficult to obtain a malaria vaccine? The 
absence of immune correlates of protection for malaria 
vaccines has been a longstanding obstacle in malaria 
vaccine  development.  The  discovery  of  a  biomarker 
which could behave as a reliable proxy of protection 
against clinical disease, together with the availability of 
a  predictive  animal  model  (currently  existing,  but Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
suboptimal)  would  make  development  efforts  much 
easier and more efficient. Many knowledge gaps will 
certainly need to be filled regarding naturally acquired 
immunity  and  its  molecular  and  epidemiological 
determinants.
The  complexity  of  the  parasite  (as  compared  to 
viruses  or  even  bacteria)  is  clearly  another  limiting 
factor. Any of the malaria plasmodia present thousands 
of  antigens,  which  differ  depending  on  the  parasite 
stage of the cycle in both the human host and vector. 
Moreover,  the  immune  responses  against  different 
stages  of  the  parasite  have  been  proven  to  vary, 
hindering the possibility of finding those who play a 
major role triggering human immunity, which would 
be the desirable candidates for a malaria vaccine. In 
addition, many antigens expressed by the parasite are 
highly  polymorphic  within  the  same  host,  adding,  if 
possible,  more  complexity  to  the  already  difficult 
process  of  antigen  identification.  In  conclusion,  no 
vaccine against parasites has been licensed yet, and this 
is not circumstantial.
Malaria  Vaccine  Approaches.  Different 
classifications  for  malaria  vaccine  candidates  have 
been use by different authors. They are based on the 
phase  of  the  parasite  cycle  they  mainly target  (and 
hence the expected disease outcome), the composition 
of  the  vaccine  itself  (whole  organism,  recombinant 
proteins  or  DNA,  and  some  of  them  adjuvated  or 
vectored),  the  vaccination  strategy  (different  dose 
schedules, prime and boost regimes), the capacity to 
interrupt  transmission  (irrespective  or  not  of  their 
effect on clinical disease) and the population they are 
intended  to  reach  (population  in  endemic  areas, 
travellers). However, some of the vaccine candidates 
act  in  different  stages  of  the  parasite  combining 
different  strategies,  making  difficult  to  create  non-
overlapping categories for any particular classification. 
The  most frequently  used classification,  which splits 
vaccine  candidates  into  pre-erythrocytic,  blood  stage 
and  transmission  blocking  vaccines,
24-26 seems 
somewhat  out  of  date  for  several  reasons.  First, 
effective  pre-erythrocytic  and  asexual  (blood)  stage 
vaccines  would  have  an  impact  on  transmission,
5
because  they  would  dramatically  decrease 
parasitaemia,  having  consequently  room  within  the 
“transmission  blocking  category”.  Second,  the  term 
“blood stage” is somewhat broad, and does not really 
specify whether they target the sexual or asexual stage 
of  the  parasite.  Therefore,  “asexual  blood  stage”  is 
probably  a  more  accurate  term.  Third,  candidates 
whose main targets are sexual stage parasites or even 
mosquito wall cells, deserve a category on their own.
Moreover,  the  impact  of  a  vaccine  targeting  a 
specific  part  of  the  cycle  may  transcend  its  stage 
specificity.  For  instance,  a  pre-erythrocytic  vaccine, 
such  as  RTS,S,  conferring  partial  pre-erythrocytic 
immunity  may  also  induce  blood  (asexual)  stage 
immunity by allowing the passage of some parasites 
(“leaky”  vaccine)  to  the  blood.  Such  low  dose 
parasitaemia  reaching  the  blood  would  contribute  to 
the  generation  of  a  local  (i.e.  blood  stage)  immune 
response,  protective  against  clinical  disease.
27
However, since the main effect of this vaccine is the 
induction  of  antibodies  against  pre-erythrocityc 
specific  antigens,  pre-erythrocytic  vaccines  as  a 
category  is  probably  still  a  valid  and  clearly 
differentiated  category  on  its  own.  In  this  review, 
vaccine candidates are classified depending on the life 
cycle stage they mainly act against.
Pre-erythrocytic  Vaccines.  These  vaccines  are 
indented to elicit an immune response against antigens 
of  the  initial  stages  of  the  infection,  i.e.  antigens 
exposed from the entrance of parasites into the blood 
(sporozoites) or hepatic stages before the parasite exits 
the liver to the blood. If a vaccine designed to follow 
this strategy were 100% effective, it would completely 
block the infecting parasites from reaching the blood 
stages, avoiding therefore any clinical symptomatology 
and  risk  of  subsequent  transmission.  Thus,  these 
malaria vaccines could conceptually protect from any 
malaria episode not only children and pregnant women 
living in malaria endemic countries, but also those who 
have not been exposed to malaria, such as travellers, 
since  they  are  at  higher  risk  of  severe  infection. 
However, if efficacy was partial and not complete, as 
phase  II  and  III  trials  seem  to  show,  the  effect  of 
vaccination  would include a  decrease  in  the  parasite 
load which is released into the blood from the liver, 
thus  minimizing  (but  not  averting)  the  effect  of  a 
malaria infection.
The first attempts to obtain a malaria vaccine were 
precisely  based  in  this  concept,  targeting  through 
attenuated  sporozoite  challenges  in  different  animals 
the  pre-erythrocytic  stages  of  malaria  infection
9.  In 
further studies, naïve volunteers were then exposed to 
UV  irradiation-weakened  sporozoites,  obtaining  a 
complete immunity in 90% of the cases, although for a 
short  period  of  time.
28 This  early  studies  aiming  to 
obtain  pre-erythrocityc  immunity,  made  scientists 
believe  that  a  malaria  vaccine  could  be  possible. 
Similarly, the  RTS,S malaria candidate vaccine, also 
pre-erythrocytic  by  design  has,  for  the  time  being, 
shown the most promising results, and is leading the 
race for being the first malaria vaccine licensed in the 
near future.
The RTS,S malaria vaccine uses a construct made 
of  the  central  repeat  region  of  the  P.  falciparum 
circumsporozoite  protein  (CSP)  and  the hepatitis  BMediterr J Hematol Infect Dis 2012; 4: Open Journal System
vimt
Figure 2. RTS,S efficacy trials against first clinical episode. Note that efficacy point estimates have been assessed at different follow up 
intervals. This chart includes only the first efficacy results of each project.
surface antigen (HBsAg) as a carrier. It is therefore a 
recombinant  subunit  vaccine.  Much  of  its  success  is 
attributed  to  the  adjuvant  systems  used  in  this 
formulation: AS02 and AS01. The first phase I trial in 
young adults in endemic areas was conducted in The 
Gambia, showing a good safety and immunogenicity 
profile with a three dose schedule,
29 but with a limited 
duration  of  protection.  Same  phase  trials  in  children 
using  RTS,S/AS02  were  conducted  in  The  Gambia 
(children 1-11 years old), with same positive results as 
in adults.
30-31 Therefore, a phase IIb efficacy study was 
conducted in 2022 Mozambican children aged 1 to 4 
years, showing efficacy against clinical malaria (first 
episode) of around 30%; against malarial infection of 
37%,  and against severe malaria  of around 58%.
32-33
Follow  up  of  participant  children  confirmed  that 
efficacy was maintained at least up to 45 months.
34 As 
a  logical  follow-up  considering  that  the  ideal  target 
population  should  be  young  infants,  another  trial 
showed  that  the  RTS,S/AS02D  malaria  vaccine  was 
safe,  well  tolerated  and  immunogenic  when 
administered  to  young  infants  in  Mozambique  on  a 
vaccination  schedule  staggered  with  other  vaccines 
belonging to the EPI schedule.
35 Trials administering 
the vaccine to infants simultaneously to the rest of EPI 
vaccines showed no  apparent interferences and good 
and similar safety and efficacy profiles.
36 Led by these 
promising  results,  a  large  phase  III  trial  with 
RTS,S/AS01  was  initiated  in  11  sites  in  7  African 
countries  including  15,460  children  of  two  different 
age categories: 6 to 12 weeks and 5 to 17 months of 
age.  The  preliminary  results  of  this  trial  have 
confirmed  the  encouraging  results  obtained  over  the 
last  decade  in  earlier  stage  trials,  with  efficacy 
estimates against first malaria episode of 50.4%, and 
against severe malaria of 45.1% (in the older cohort). 
The combined efficacy against severe malaria in both 
age categories (children  6 weeks to  17 months)  was 
34.9%. There were no differences in the safety profile 
of  malaria  vaccinated  children  compared  with  the 
control  group.
37 Further  results  on  safety  and 
immunogenicity of this vaccine will be published by 
the end of the study which has been scheduled in 2013. 
(Figure 2) This study, cofunded as the earlier trials of 
RTS,S  by  GSK,  and  the  Malaria  Vaccine  Initiative 
(MVI)  at  PATH,  has  been  the  largest  trial  ever 
conducted in children in this continent.
Other  attempts to  obtain  a  vaccine  inducing  pre-
erythrocytic with whole parasites (sporozoites) in the 
past and a renewed interest has recently been observed 
in these types of vaccines. An early study consisted of 
exposing  healthy  volunteers  to  the  inoculation  of Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
radiation-attenuated  P. falciparum sporozoites  by 
mosquito bites.
38 It showed a 93% protection, although 
the number of subjects in this trial was limited (only 14 
subjects).  Another  recent  study  made  in  the 
Netherlands  tried  to  induce  immunity  in  challenged 
subjects through the inoculation of  intact sporozoites 
by  means  of  mosquito  bites  while  receiving  a 
prophylactic regimen of chloroquine.
An  homologous  challenge  after  discontinuation  of 
chloroquine  showed  the  induction  of  cell  mediated
protective  immunity.
39 A  further  study  suggests  that 
this protection might last up to 2 years after artificial 
immunization.
40
The  approach  of  an  American  biotech  company 
using  the  whole  parasite  strategy  was  to  develop  a 
vaccine that could be administered applying the same 
principles  of  radiation-attenuated  P. falciparum
sporozoites  (since  exposing  vaccine  recipients  to 
mosquito  bites  is  not  a  realistic  option).
41 They 
obtained  a  vaccine  using  parasites  from  mosquito’s 
salivary  glands,  irradiated  them  and  subsequently 
criopreserved them in liquid nitrogen. The first phase I 
clinical trial began in May 2009 and included the skin 
inoculation  of  this  vaccine  (known  as  PfSPZ)  to  80 
healthy US volunteers, but failed to show the expected 
protection seen in historical trials.
42 Newer possibilities 
to  mimic  the  effect of irradiated sporozoites through 
mosquito  bites  could  be  the  development  of  an 
intravenous  vaccine or  the recent  strategy  using  non 
irradiated  genetically  attenuated  parasites,  but  these 
alternatives still need to be explored.
Prime  boost  vector  malaria  vaccines.  This  is  an 
innovative and promising strategy which mainly targets 
liver  stage  antigens  through  the  combination  of 
different  regimes  and  vaccine  composition.  Several 
studies in animal models have been conducted using 
different  mixtures  of  prime  and  boost  immunization 
combinations  using  viral  vectors  which  express 
different  P.  falciparum antigens  and  DNA  plasmids 
(encoding  the  same  antigen  expressed  in  the  viral 
vector). A few antigens (mainly pre-erythrocytic) have 
been targeted by both viral vectors and DNA plasmids 
used alone or in prime boosting regimes, although the 
thrombospondin-related  adhesive protein (TRAP) has 
conferred the best immunogenicity. Likewise, several 
viral vectors (vaccinia virus, fowlpox, modified Ankara 
virus,  adenovirus)  have  been  tried  out.
43 The  use  of 
single DNA plasmids encoding TRAP is limited since 
they have only demonstrated to induce CD8 immunity 
in  animal  models  failing  to  do  so  in  humans
44. 
However, viral vectors have been shown to induce both 
humoral  and  cell  mediated  immunity.
21,  45 A  further 
extension by Draper and colleagues in animal models 
have  shown  that  a  prime  boost  strategy (including 
adenovirus  type  5  and  Modified  Vaccinia  Virus 
Ankara(MVA) expressing MSP-1) regime is capable of 
inducing powerful blood stage antibody responses and 
can elicit a cell mediated response while reducing the 
parasite  load  at  the  liver.
20,46 At  the  moment,  the 
leading  vaccine  using  a  prime  boost  regime  (which 
includes a heterologous Chimpanzee Adenovirus and a 
MVA)  is  entering  a  phase  Ib  safety  and 
immunogenicity  trial  in  Africa.
43 Much  is  expected 
from  these  vaccine  platforms,  although  the  critical 
trials in malaria endemic countries still need to confirm 
what has been found in the early studies.
Asexual Blood-Stage Vaccines. Asexual blood stage 
vaccines are those whose objective is  preventing the 
erythrocyte  invasion  and  blocking  the  infected  red 
blood cells from adherence to several tissues, which is 
indeed  the  onset  of  a  clinical  malaria  disease.  They 
would  not  be  effective  towards  preventing  infection; 
they would rather mitigate the clinical symptoms of a 
malaria episode. Some authors suggest that this type of 
vaccines  would  need  to  be  combined  in  a 
multicomponent vaccine with perhaps pre-erythrocityc 
or sexual stage components. It is known that natural 
immunity  against  blood  stage  antigens  can  be 
induced,
47 and perhaps it might also play a major role 
in the long lasting protection shown by RTS,S malaria 
vaccine,  due  to  the  occurrence  of  “leaky”  immunity 
when pre-erythrocytic immunity wanes.
27
Most  asexual  stage  vaccine  candidates  target  the 
induction  of  antibody  response  against  merozoite 
antigens.  The  targeted  antigens  which  have  been 
evaluated for impact in  malaria exposed children are 
the  apical  membrane  protein  (AMA1),  merozoite 
surface protein 1 (MSP1), 2 (MSP2) and 3 (MSP3), the 
glutamate-rich  protein long synthetic  peptide vaccine 
(GRURP), the ring-infected erythrocyte surface antigen 
(RESA),  serine  repeat  antigen  (SERA5)  and 
erythrocyte-binding  antigen  175  (EBA  175).
48 Most 
clinical  trials  have  not  shown  significant  impact  on 
preventing  clinical  malaria  although  some  of  them 
have shown to reduce parasite density.
49-50 The absence 
of  correlates of protection  and  antigenic  variation  of 
blood  stage  antigens  still  are  some  of  the  major 
problems of this type of vaccines.
18
The results of a field trial conducted in Mali with a 
malaria vaccine based on AMA1 have been recently 
published.  Efficacy  against  the  primary  endpoint 
(clinical malaria) was poor, only 17.4% (hazard ratio 
0.83,  95%  CI  0.63  to  1.09),  although  the  strain 
specific-efficacy (against malaria caused with parasites 
with AMA1 included in the vaccine) was much higher, 
suggesting  that  it  might  be  worth  considering  this 
construct for a multicomponent malaria vaccine.
50
Another innovative strategy to induce asexual blood 
stage  immunity implies  the  inoculation  of  red  blood Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
cells  with  whole  attenuated  merozoites,  in  order  to 
provoke a cell mediated response. This challenge trial 
has  been  successfully  conducted  by  Pombo  et  al in 
Australia.
47 They  challenged  5  healthy  subjects  by 
inoculating infected red blood cells followed by drug 
cure. In the 4
th round, before the drug cure, they could 
not  find  any  parasites  or  antibodies  in  the  blood  of 
these subjects, but rather a proliferative T cell response 
involving CD4 and CD8 cells.
47,51 Further trials with 
larger amount of subjects are needed to confirm these 
results if some logistic and technical issues involving 
the use of human blood and growth of merozoites can 
be overcome. 
Sexual Stage Vaccines. This category would include 
most of the classical transmission  blocking vaccines, 
term now embraced by the recent concept of “vaccines 
that interrupt malaria transmission” (VIMT). Vaccines 
that  target  the  sexual  stage  of  Plasmodia would  not 
protect the vaccinated recipient from a malaria episode, 
but rather the community the subject belongs to (reason 
why they were also called “altruistic” vaccines). These 
vaccines would avoid the  fertilization process of the 
gametes or the invasion in the mosquito midgut, and 
prevent  from  further  development  in  the  vector, 
therefore interrupting the transmission of the disease to 
the  subsequent  individuals.  Although  the  immune 
mechanisms have not yet been fully understood, it is 
thought  that  the  sexual  stage  specific  antibodies, 
together with cytokines and the complement, would be 
taken by the mosquito in the blood meal, interfering 
with  the  formation  of  a  new  oocyst  in  the  vector 
midgut.
52 There are four main antigens that have been 
targeted  in  vaccine  preclinical  trials:  P230,  P48/45, 
which are proteins from the gametocyte and P28 and 
P25 which are proteins from the zygote or ookynete 
stage.
52 The latter, P25, is the target of the only sexual 
stage candidate that has reached the clinical phase of 
development.  However,  should  these  candidates  be 
considered  for  the  interruption  of  transmission,  they 
would need to be applied to a large proportion of the 
population of the area (since any infected person would 
be  capable  of  transmitting  malaria),  raising  further 
technical and regulatory issues.
Vaccines  against  vector  molecules.  Another  vaccine 
project that would have a high impact on transmission 
of  any  Plasmodium  species  would  be  a  vector 
stage/ookinete  stage  vaccine  targeting  mosquito’s 
midgut  molecules,  which  are  essential  for  parasite 
growth  within  the  mosquito.
53 It  has  been  recently 
shown  that  ookinete  invasion  could  be  inhibited  by 
antibodies  against  aminopeptidase  N  (AgAPN1),  a 
midgut  surface  antigen
54.  Nonetheless,  in  case  an 
effective vaccine based on mosquito midgut antigens 
could  be  developed,  major  deployment  complexities 
would also need to be addressed. 
Other Vaccines
Vaccines  against  P  Vivax.  Although  greater  efforts 
have been dedicated to vaccines against P. falciparum, 
there is a growing interest on eliciting a vaccine against 
P. vivax, the most widespread malaria species in the 
world, especially in South and Central America, certain 
Middle  Eastern  countries  and  Asia  and  the  South 
Pacific. P. vivax is not as deadly as P. falciparum, but 
causes considerable morbidity and consumes not few
health  resources.  Several  difficulties  have  been 
encountered to develop P. vivax vaccines. Besides the 
lack  of  resources  allocated  for  P. vivax vaccine 
research, there have been few P. vivax target antigens 
identified  with  vaccine  potential,  as  compared  to  P.
falciparum: the CS protein, SSP2/MTRAP, the Duffy 
binding protein, the MSP1, the AMA1, P25 and P28.
55
The different behavior of the parasite within the human 
host  and  the  probably  different  immune  response 
induced by P. vivax (compared to P. falciparum) adds 
a  lot  of  complexity  to  vaccine  development.
56 There 
have  been  several  preclinical  trials  and  sporozoite 
challenge trials with P. vivax vaccines but up to our 
knowledge, there have been few phase I clinical trials 
(no phase II trials yet). The two main targets tested at 
phase  I  clinical  phase  are  P. vivax circumsporozoite 
(CS)
57-58 and P25.
59-60 There is an ongoing phase I/IIa 
trial based on a CS protein with the AS01B adjuvant 
currently being conducted in malaria naïve individuals 
by  the  U.S.  Army  Medical  Research  and  Materiel 
Command (USAMRMC)
Malaria vaccines for pregnancy. Most malaria vaccine 
candidate  trials  entering  clinical  phases  in  malaria 
endemic  countries  have  taken  children  as  study 
population.  The  rational  is  that  they  are  the  most 
vulnerable  group  for  malaria,  enduring  higher 
morbidity and mortality. In case these vaccines provide 
lifelong  protection,  greater  advantage  would  be 
obtained by vaccinating at early stages of life. In case 
the  RTS,S  malaria  vaccine  is  licensed,  it  would 
probably be delivered with other childhood vaccines. 
However, in case the duration of protection is shorter, 
it  is  reasonable  to  think  that  periodical  or  boosting 
vaccination would be needed to protect populations at 
different stages of life. The other major high risk group 
for malaria, apart from children, towards which greater 
efforts  need to  be  made to  guarantee  protection,  are 
pregnant  women,  who  are  highly  vulnerable  to  the 
disease in endemic areas. The existing knowledge gaps 
in malaria in pregnancy immunology and pathogenesis 
adds complexity to the objective of eliciting effective 
vaccines  to  provide  protection  to  mothers,  fetus  and 
newborns. 
One of these gaps involves the binding of parasitized Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 2 summarizes a list of vaccine candidates currently under clinical development.
Vaccine Project name
[Trial registration number]*
Antigen Adjuvant Clinical 
Phase
Trial Sponsor Comments
Pre-erythrocytic Projects
RTS,S/AS01E
[NCT00866619]
CSP (207-395) & 
HepBsAg AS01 III GSK First results phase III 
already published
AdCh63/MVA ME-TRAP
[NCT01142765, NCT00890760]
TRAP + ME epitopes 
(CS, LSA1, LSA3, 
STARP, EXP1, pb9)
I/IIa, 
I/IIa OX Administered in a Prime-
Boost regime
Adenovirus (Ad35) vectored 
CS [NCT00371189 and 
NCT01018459]
CSP Ia, Ib NIAID
Polyepitope DNA EP1300
[NCT01169077]
CSP, SSP2/TRAP, 
LSA-1, EXP-1 Ia NIAID DNA vaccine
Adenovirus (Ad35) and 
adenovirus 26 (Ad26) vectored 
CS in heterologous prime-
boost regimen [NCT01397227]
CSP I/IIa Crucell Administered in a Prime-
Boost regime.
Adenovirus (Ad35) vectored 
CS and RTS,S-AS01 in 
heterologous prime-boost 
regimen [NCT01366534]
CSP I/IIa GSK Administered in a Prime-
Boost regime.
Adenovirus (Ad26) vectored 
CS; Adenovirus (Ad35) 
vectored CS
CSP I NIAID Administered in a Prime-
Boost regime.
PfCelTOS FMP012
CelTOS (cell-
traversal protein for 
ookinetes and 
sporozoites)
USAMRMC
Pf GAP p52-/p32- (Genetically 
Attenuated Sporozoites)                                     
[NCT01024686]
Genetically 
attenuated whole 
Plasmodium 
falciparum organism
I/IIa
Seattle Biomedical 
Research Institute 
(Seattle Biomed) 
(USA)
Genetically attenuated 
whole organism
PfSPZ: metabolically active, 
non-replicating malaria 
sporozoite vaccine
[NCT01001650, 
NCT01441167]
Sanaria, Inc. (USA) I/IIa, I
PfSPZ Vaccine Radiation 
Attenuated Sporozoite Vaccine 
(Single Strains)
Sanaria, Inc. (USA) I/IIa Intravenous administration, 
whole organism
Asexual Blood-stage Projects
AdCh63/MVA MSP1
[NCT01003314, NCT01142765] MSP1 I/IIa, 
I/IIa OX Administered in a Prime-
Boost regime.
EBA175 RII
[NCT00347555, NCT01026246]
EBA175 RII, non-
glycosylated
aluminiu
m-
phospahte
Ia, Ib NIAID
FMP2.1/AS02A (AMA-1 3D7 
E. 
coli-expressed in AS02A 
adjuvant)   [NCT00385047, 
NCT00349713, NCT00358332, 
NCT00460525]
AMA-1 ( 83(Gly) to 
531(Glu)) AS02A
Ia, I/IIa, 
Ib, Ib, 
Iib
USAMRMC
FMP2.1/AS01B (AMA-1 3D7 
E. coli expressed in ASO1B 
adjuvant)
[NCT00385047]
AMA-1 (the 
ectodomain amino 
acids 83(Gly) to 
531(Glu))
AS01B I/Iia USAMRMC
FMP010/AS01B (MSP-1 42 
FVO E. coli-expressed in 
AS01B adjuvant)
[NCT00666380]
MSP-1, p42 subunit AS01B Ia USAMRMC
GMZ2[NCT00397449] GLURP, MSP3
Alum, 
DDA-
TDB
Ia EVIMediterr J Hematol Infect Dis 2012; 4: Open Journal System
GMZ2 field [NCT00424944, 
PACTR2010060002033537] GLURP, MSP3 Alum Ib, II AMANET
MSP3 (181-276)  MSP3
Alum, 
Montanid
e ISA 720
EVI
MSP3 [181-276] field
[NCT00452088, NCT00469651, 
NCT00652275]
MSP3 Alum Ib, Ib, 
IIb EVI, AMANET
SE36 [ISRCTN71619711] N-terminal of 
SERA5.
Aluminu
m 
hidroxide 
gel
Ib BIKEN
JAIVAC (MSP1 19/EBA175)  
[CTRI/2010/091/0003101] MSP1 19/EBA175 Mon ISA 
720 I ICGEB/EVI Mixture of two recombinant 
proteins
AMA1-C1/Alhydrogel
®+ CPG       
7909 [NCT00984763, 
NCT00344539, NCT00414336]
AMA1-C1: mixture 
of two AMA1 
proteins, AMA1-FVO 
and AMA1-3D7, 
mixed in a 1:1 ratio
Alhydroge
l® 
CPG7909
I/IIa, Ia, 
Ib NIAID
BSAM-2/Alhydrogel®+CPG
7909 [NCT00889616]
BSAM-2 is a mixture 
of two MSP1 42 
proteins, MSP1 42-
FVO and MSP142-
3D7; and two AMA1 
proteins, AMA1-FVO 
and AMA1-3D7, 
mixed in a 1:1:1:1 
ratio
Alhydroge
l® 
CPG7910
Ia, Ib NIAID
AdCh63 AMA1/MVA AMA1
[NCT01095055, NCT01142765]
AMA1 (biallelic 
codon-optimised 
construct with 3D7, 
FV0 and common 
epitopes, with tPA 
leader sequence)
I, IIa OX Administered in a Prime-
Boost regime.
NMRC-M3V-Ad-PfCA 
NMRC-M3V-Ad-PfCA
[NCT00392015]
CSP (3D7 strain) and 
AMA1 (3D7 strain) I/IIa USAMRMC
Combination vaccine (pre-
erythrocytic and blood 
stage)
NMRC-M3V-D/Ad- PfCA
[NCT00870987]
CSP (3D7 strain) and 
AMA1 (3D7 strain) I/Iia USAMRMC
Combination vaccine (pre-
erythrocytic and blood 
stage). Prime Boost regime
CSP, AMA1 virosomes (PEV
301,302)  [NCT00400101,
NCT00513669]
AMA-1 and CS 
mimotopes Ia, Ib STI
Combination vaccine (pre-
erythrocytic and blood 
stage). Virosomal vaccine
ChAd63/AMA MVA/AMA1 
+alhydrogel/CPG7909 
[NCT01351948]
AMA1
CPG 
7909, 
alhydrogel
I OX Administered in a Prime-
Boost regime.
Sexual stage projects
Pfs25-EPA/Alhydrogel 
[NCT01434381] Pfs25-EPA Alhydroge
l I NIAID
Recombinate Protein 
conjugated to Pseudomonas 
aeruginosa EPA
P. vivax Project
VMP001/AS01B  
[NCT01157897]
Plasmodium vivax 
CSP AS01B I/IIa USAMRMC Chimeric Reombinant 
Protein
Alphabetical list of abbreviations: AMA, Apical Membrane Antigen; AMANET, African Malaria Network Trust; BIKEN, Research 
Foundation for Microbial Diseases of Osaka University; CSP, Circumsporozoite protein; EPA, ExoProtein A; EVI, European Vaccine 
Initiative; GSK, GlaxoSmithKline Biological; GLURP, Glutamate-rich protein;  ME-TRAP, Multi Epitope - thrombospondin-related 
adhesive protein; MVA, Modified Vaccine Ankara; MSP, Merozoite Surface Protein; NIAID National Institute of Allergy and Infectious 
Diseases (USA);NIH, National Insitute of Health; OX, University of Oxford (UK); SERA, Serine Repeated Antigen; STI, Swiss Tropical 
Institute; USAMRMC, U.S. Army Medical Research and Materiel Command.
*If starting by NCT, registered at clinicaltrials.gov; by CTRI, at Clinical Trials Registry, India; by ISRCTN, at International Standard
Randomized Controlled Trial Number Register; by PACTR, at Pan African Clinical Trials Registry.
erythrocytes  to  the  chondroitin  sulfate  A (CSA), a
glycosaminoglycan  receptor found  throughout  the 
placenta syncytiotrophoblast, which is thought to be a 
key  mechanism  to  produce  disease  in  pregnant 
women.
61 Experimental  studies  with  recombinant 
var2csa,  a  member  of  the P.  falciparum erythrocyte Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
membrane protein 1 (PfEMP1), have shown that it is 
possible to obtain antibodies inhibiting the adherence 
of infected  erythrocytes  to  CSA.
62 Thus,  it  has been 
suggested that var2csa would be the ideal candidate for 
a  malaria  vaccine  especially  designed  for  pregnant 
women.
63 However, other receptors could also play an 
important  role  in  the  adherence  of  the  infected 
erythrocytes to the placenta,
64 and it is not clear why 
several studies have failed to show association between 
different levels of IgGs against CSA binding infected 
erythrocytes and placental malaria infection.
65
Establishing a conceptual framework for vaccines to 
prevent  malaria  during  pregnancy  seems  a  key  step. 
This would require designing of specific target product 
profiles for mothers, fetus and newborns, which should 
be accompanied by the crucial allocation of funds to 
identify specific target antigens and conduct of clinical 
trials for this particular risk group.
61
Table  2 summarizes  a  list  of  vaccine  candidates 
currently under clinical development.
Vaccines  that  Interrupt  Malaria  Transmission 
(VIMT).  Embedded  within  the  malERA  initiative,  a 
rigorous  scientific  consultative  process  to  identify 
knowledge gaps and new tools that will be needed to 
eradicate malaria globally,
6 the Consultative Group on 
Vaccines  introduced  the  concept  of  vaccines  that 
interrupt  malaria  transmission  (VIMT).  This  concept 
would include vaccines whose implementation would 
entail a significant reduction in the transmission of the 
disease.  For  example,  vaccines  targeting  the  sexual 
stages of the parasite in the blood and in the mosquito, 
those disrupting the development of the parasite inside 
the  vector and those pre-erythocytic and blood stage 
vaccines  that  would  ultimately  reduce  sexual  and 
asexual stage parasite rates.
5 A target product profile 
(TPP),  which  is  a  series  of  characteristics  that  a 
candidate product under development should take into 
account, has been proposed by this group of experts 
and is partially shown in table 3. We include here the 
desired target of a vaccine that aims to have an impact 
on transmission, although  the  original TPP  proposed 
also includes a list of minimally acceptable targets for 
a VIMT.
5
Among  the  different  research  and  development 
priorities concerning VIMT, the need for greater efforts 
in  vaccine  development  against  other  species  of 
Plasmodia  different  to  P.  Falciparum is  stressed 
(mainly P. vivax), due to the considerable burden of 
disease they are responsible for, and because targeting 
these specific species is considered critical to achieve 
malaria eradication. Other priorities would be: 1) in the 
field of vaccine evaluation, harmonizing the available 
tools  for  measurement  of  transmission  rates  and 
developing new surrogates for malaria transmission in 
a  community  level  from  individual  level  immune 
responses. 2) Further research is needed in the field of 
transmission  dynamics  and  the  biology  of  malaria 
parasites,  since  very  little  is  known  on  what  strains 
would prevail as transmission falls, or whether there 
would be a niche for re-emergent parasites. 3) Delivery 
systems  for  multicomponent  vaccines  need  to  be 
developed  since  no  studies  about  compatibilities  of 
these components have been conducted 4) Research on 
the immune activation by adjuvants will be crucial to 
design  new  vaccines  that  could  accompany  new 
recombinant protein-based  vaccines. 5) Designing  an 
effective vaccine that could induce humoral immunity 
against the midgut epithelium of the vector would be of 
immense  utility,  since  it  would  prevent  human 
infection by any species of Plasmodium.
Other Challenges for Malaria Vaccines. Apart from 
the  biological  challenges  in  malaria  vaccine 
development,  there  are  other  financial,  technical, 
regulatory and logistical issues which will eventually 
need to be considered. The lengthy process and high 
costs  of  developing  a malaria  vaccine  are  clear 
drawbacks  for  pharmaceutical  companies  aiming  to 
develop them. Indeed, it has been estimated that from 
conception to licensure, a malaria vaccine could need 
at  least  15  years  of  clinical  development  and  cost
Table 3. Target Product Profile for Vaccines that Interrupt Malaria Transmission: (Desired target)
 Indication. The vaccine should provide protection against P. falciparum and P. vivax malaria so that Reffective<1.
 Target population. It should be administered to all age groups and populations, including pregnant women, persons with 
immunodeficiencies, malnourished individuals or other high risk populations
 Route of administration. The vaccine would be administered orally or by intramuscular or subcutaneous injection.
 Product presentation. It would be available in a single dose auto-disposable compact prefilled device
 Dosage schedule. A single dose vaccine that can be administered by either mass administration of clinic based programs.
 Safety. The vaccine should have a safety and reactogenicity profile comparable to hepatitis B vaccine.
 Expected efficacy. It  would reduce Reffective below 1.0  in a malaria endemic population and provide protection  against P. 
falciparum and P. vivax for at least 2 years.
 Coadministration. The vaccine should be coadministered with any licensed vaccine without a clinically significant interaction 
to safety or immunogenicity
 Shelf life. The product must have a minimum shelf life of 36 months.
 Storage. The product should be stable at room temperature and withstand freeze thawing
 Product registration. Product must be WHO prequalified and registered with EMEA and FDA
*Adaptation from the Target Product Profile (TPP) proposed by the malERA Consultative Group on Vaccines.
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around 500 to 1000 million US dollars.
67 In fact, the 
RTS,S phase three clinical  trial could not have been 
possible without the partnership of the pharmaceutical 
industry  with  non-profit  institutions,  such  us  PATH-
MVI and the Bill and Melinda Gates Foundation. As 
vaccine  development requires  such  significant 
investment,  new  malaria  vaccine  candidates  would 
need  to  show  considerable advantages  compared  to 
RTS,S  before  entering  clinical  development. 
Consequently,  this  would  probably  meanthat  any 
vaccine  aimed  to  be  approved  by  any  regulatory 
agency will probably need to face non inferiority trials, 
which would further increase the costs. In the ladder of 
vaccine  research,  human  challenge  models  are  more 
and  more  believed  to  be  crucial  in  order  to  decide 
which projects will enter advanced phases of clinical 
research. In the current context of the global economic 
crisis,  fundraising  for  malaria  vaccine  development 
will  not  be  an  easy  task.  Although  malaria  is 
considered  one of the  “big  killers”, this  disease will 
have  to  compete  with  others,  such  as  AIDS  or 
tuberculosis, and with other vaccines that have shown 
great efficacy but have not yet been implemented in 
many countries in the world.
Implementing  a  successful  childhood  vaccination 
campaign  in  developing  countries  is  not  a  trivial 
undertaking. Engaging  all  stakeholders  of  the public 
health  sector  is  one  crucial  element,  as  well  as 
optimizing  and  strengthening  existing  delivery 
methods. Any  malaria  vaccine  targeting  those  who 
most  need  it  (children)  would  need  to  be  staggered 
within  the  EPI  calendar  in  order  to  be  technically 
feasible.  Should  malaria  vaccines  need one  or  more
booster doses (a possibility currently being assessed for 
RTS,S),  further  delivery  approaches  will  need  to  be 
developed.  It  would  be  desirable  to  administer  any 
booster dose together with other EPI vaccines (such us 
measles  at  9  months);  however,  depending  on  the 
immunological  profile  of  the  vaccine,  specific  mass 
vaccination campaigns would need to be implemented, 
which will surely have to deal with complex logistical 
issues  in  areas  where  access  to  health  systems  is 
limited,  as  well  as  difficulties  related  to  suboptimal 
cold  chains,  stock  management  limitations  or 
undertrained health care personnel, among others.  
Conclusions. Many questions remain to be answered 
regarding  malaria  vaccine  research.  Should the 
preliminary  results  of  the  phase  III  trial  of  RTS,S 
malaria vaccine candidate are confirmed, the goal of 
licensing the first malaria vaccine will soon become a 
reality. However, since this vaccine will not be fully 
efficacious,  second  generation  vaccines  with  greater 
protection and perhaps targeting different stages of the 
parasite cycle (combination vaccines) will be needed. 
An intervention like a malaria vaccine must surmount 
formidable  biological  and  immunological  challenges 
during development. Furthermore, logistical, technical 
and  economic  realities  pose  challenges  which 
scientists,  health  care  workers,  politicians  and 
communities need to broach successfully for effective 
implementation,  reaching  all  those  who  need 
vaccination, to be realized. Only then, the fascinating 
prospects  of  malaria  eradication  will  become  more 
realistic.
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